Macrogenics (MGNX) Net Income towards Common Stockholders (2012 - 2026)
Macrogenics (MGNX) posted quarterly Net Income towards Common Stockholders of -$38.9 million for Q1 2026, up 8.91% year-over-year from -$35.7 million in Q1 2025, and down 175.42% quarter-over-quarter from -$14.1 million in Q4 2025.
Powered by 
Analysis
Macrogenics (MGNX) Net Income towards Common Stockholders (2012 - 2026) Analysis & Trends
Macrogenics (MGNX) has reported Net Income towards Common Stockholders for 15 consecutive years, with -$38.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Income towards Common Stockholders rose 8.91% year-over-year to -$38.9 million; the TTM figure through Mar 2026 stood at -$72.5 million (down 26.04% YoY), while the FY2025 annual figure was -$74.6 million, down 11.39% from the prior year.
- Net Income towards Common Stockholders declined to -$38.9 million in Q1 2026 per MGNX's latest filing, from -$14.1 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $56.3 million in Q3 2024 and bottomed at -$100.2 million in Q1 2024.
- Historically, Net Income towards Common Stockholders has averaged -$31.2 million across 5 years, with a median of -$38.9 million in 2026.
- Annual changes were most pronounced in 2023 — Net Income towards Common Stockholders plunged 511.87% — and 2024, when it surged 258.61%.
- Macrogenics' Net Income towards Common Stockholders stood at $12.0 million in 2022, then slumped by 511.87% to -$49.4 million in 2023, then soared by 68.75% to -$15.4 million in 2024, then advanced by 8.39% to -$14.1 million in 2025, then tumbled by 175.42% to -$38.9 million in 2026.
- Business Quant data shows MGNX's Net Income towards Common Stockholders at -$38.9 million in Q1 2026, -$14.1 million in Q4 2025, and $16.8 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.74 Bn | 130.89 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.52 Bn | 77.52 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.04 Bn | 52.91 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.06 Bn | 44.06 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 39.98 Bn | 34.88 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.46 Bn | 32.15 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Macrogenics | 277.59 Mn | 163.68 Mn | - | 19.52 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 19.52 Mn |
| Mar 31, 2026 | -38.33 Mn |
| Dec 31, 2025 | -14.13 Mn |
| Sep 30, 2025 | 16.82 Mn |
| Jun 30, 2025 | -36.25 Mn |
| Mar 31, 2025 | -42.72 Mn |
| Dec 31, 2024 | -15.42 Mn |
| Sep 30, 2024 | 56.31 Mn |
| Jun 30, 2024 | -55.66 Mn |
| Mar 31, 2024 | -54.88 Mn |
| Dec 31, 2023 | -49.35 Mn |
| Sep 30, 2023 | -35.50 Mn |
| Jun 30, 2023 | -45.74 Mn |
| Mar 31, 2023 | -39.08 Mn |
| Dec 31, 2022 | 11.98 Mn |
| Sep 30, 2022 | -24.96 Mn |
| Jun 30, 2022 | -41.81 Mn |
| Mar 31, 2022 | -66.64 Mn |
| Dec 31, 2021 | -58.24 Mn |
| Sep 30, 2021 | -52.99 Mn |